Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Eric Wu

Concepts (357)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
28
2022
381
3.980
Why?
Everolimus
10
2016
61
2.570
Why?
Health Resources
8
2022
120
2.410
Why?
Cost of Illness
12
2022
254
2.190
Why?
Receptor, ErbB-2
9
2016
300
1.600
Why?
Breast Neoplasms
12
2016
1846
1.540
Why?
Medication Adherence
6
2016
531
1.280
Why?
Hyperkalemia
2
2020
26
1.260
Why?
Receptors, Estrogen
3
2015
371
1.240
Why?
Receptors, Antigen, T-Cell
4
2021
615
1.240
Why?
Immunotherapy, Adoptive
2
2020
184
1.210
Why?
Health Expenditures
6
2020
172
1.090
Why?
Practice Patterns, Physicians'
4
2016
1175
1.070
Why?
Health Services
6
2016
103
0.980
Why?
United States
39
2022
12137
0.950
Why?
Receptors, Progesterone
2
2015
319
0.870
Why?
Models, Economic
2
2020
48
0.850
Why?
Hepatitis C, Chronic
2
2015
150
0.850
Why?
Middle Aged
52
2020
26605
0.840
Why?
Antifungal Agents
4
2017
128
0.810
Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
97
0.800
Why?
Antineoplastic Agents
9
2016
1875
0.790
Why?
Aged
38
2022
18969
0.780
Why?
Retrospective Studies
31
2022
12521
0.770
Why?
Hospital Costs
3
2020
104
0.740
Why?
Antineoplastic Combined Chemotherapy Protocols
9
2016
1356
0.720
Why?
Gout
2
2012
36
0.720
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
256
0.700
Why?
Female
63
2021
59324
0.680
Why?
Nocturia
1
2019
7
0.670
Why?
Hospitalization
13
2021
1762
0.660
Why?
Proportional Hazards Models
12
2017
1078
0.640
Why?
Kaplan-Meier Estimate
10
2017
813
0.630
Why?
Cost-Benefit Analysis
12
2022
544
0.620
Why?
Depressive Disorder, Major
3
2011
301
0.620
Why?
Humans
80
2022
114045
0.610
Why?
Nutrition Surveys
1
2019
225
0.600
Why?
Male
53
2021
55396
0.600
Why?
Proline
2
2015
72
0.590
Why?
Candida
2
2017
32
0.590
Why?
Adult
41
2022
30375
0.580
Why?
Medicare
7
2022
661
0.570
Why?
Prevalence
10
2020
2247
0.570
Why?
Fluconazole
1
2017
16
0.570
Why?
Candidemia
1
2017
7
0.560
Why?
Myocardial Perfusion Imaging
1
2017
34
0.560
Why?
Cardiologists
1
2017
40
0.550
Why?
Tomography, Emission-Computed, Single-Photon
1
2017
75
0.550
Why?
Fees, Pharmaceutical
3
2016
13
0.540
Why?
Oligopeptides
2
2015
234
0.540
Why?
Thrombolytic Therapy
1
2017
117
0.530
Why?
Renal Insufficiency, Chronic
2
2020
486
0.530
Why?
Insurance Claim Review
8
2017
68
0.520
Why?
Antirheumatic Agents
2
2016
255
0.520
Why?
Hypoglycemic Agents
2
2015
1011
0.510
Why?
Biological Therapy
1
2016
26
0.510
Why?
Citalopram
3
2011
28
0.500
Why?
Tissue Plasminogen Activator
1
2017
204
0.500
Why?
Databases, Factual
8
2016
1125
0.500
Why?
Drug Eruptions
1
2015
26
0.490
Why?
Psoriasis
3
2012
80
0.480
Why?
Fibrinolytic Agents
1
2017
231
0.480
Why?
Comparative Effectiveness Research
2
2012
131
0.470
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
296
0.470
Why?
Liver Neoplasms
2
2015
504
0.470
Why?
Diphosphonates
2
2012
51
0.460
Why?
Delivery of Health Care
2
2019
828
0.460
Why?
Physicians, Primary Care
1
2017
222
0.450
Why?
Anemia
1
2015
143
0.450
Why?
Brain Ischemia
1
2017
297
0.450
Why?
Imidazoles
2
2012
203
0.440
Why?
Antiviral Agents
2
2015
642
0.420
Why?
Dextroamphetamine
1
2012
3
0.410
Why?
Aged, 80 and over
11
2020
6306
0.400
Why?
Referral and Consultation
1
2017
632
0.400
Why?
Methylphenidate
1
2012
36
0.400
Why?
Hypertension
4
2018
1052
0.400
Why?
Drug Delivery Systems
1
2015
295
0.390
Why?
Pulmonary Embolism
1
2014
180
0.390
Why?
Drug Costs
6
2015
92
0.380
Why?
Schizophrenia
2
2006
412
0.380
Why?
Neoplasm Metastasis
6
2016
521
0.380
Why?
Fumarates
1
2011
10
0.370
Why?
Drugs, Generic
1
2011
18
0.370
Why?
Drug Substitution
1
2011
46
0.360
Why?
Postmenopause
4
2016
301
0.360
Why?
Central Nervous System Stimulants
1
2012
140
0.360
Why?
Bone Diseases
1
2011
57
0.350
Why?
Venous Thromboembolism
1
2014
230
0.350
Why?
Stroke
2
2017
1019
0.350
Why?
Angiotensin Receptor Antagonists
1
2011
76
0.350
Why?
Arthritis, Rheumatoid
2
2016
1002
0.350
Why?
Amides
1
2011
87
0.350
Why?
Diabetes Mellitus, Type 2
2
2015
2087
0.340
Why?
Diabetes Mellitus
1
2018
898
0.340
Why?
Multiple Myeloma
1
2011
98
0.340
Why?
Anticoagulants
1
2014
547
0.340
Why?
Crohn Disease
5
2012
196
0.330
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
180
0.330
Why?
Insurance, Health
3
2011
243
0.330
Why?
Antibodies, Monoclonal
6
2011
1257
0.320
Why?
Sick Leave
2
2007
13
0.320
Why?
Risk Factors
12
2017
8614
0.320
Why?
Hyperuricemia
1
2009
43
0.320
Why?
Quality of Life
8
2021
2343
0.320
Why?
Heart Failure
2
2020
1958
0.320
Why?
Patient Acceptance of Health Care
7
2021
675
0.310
Why?
Disease-Free Survival
5
2016
618
0.310
Why?
Antineoplastic Agents, Hormonal
3
2016
138
0.310
Why?
Attention Deficit Disorder with Hyperactivity
1
2012
363
0.310
Why?
Costs and Cost Analysis
7
2019
196
0.310
Why?
Absenteeism
2
2005
40
0.300
Why?
Comorbidity
8
2014
1447
0.300
Why?
Uric Acid
1
2009
148
0.300
Why?
Neoplasm Recurrence, Local
2
2015
850
0.300
Why?
Insulin
2
2015
2080
0.290
Why?
Head and Neck Neoplasms
1
2012
427
0.290
Why?
Physicians
1
2015
765
0.290
Why?
Insurance Claim Reporting
2
2007
21
0.290
Why?
Hypoglycemia
1
2012
386
0.280
Why?
Young Adult
12
2020
10444
0.270
Why?
Triazoles
3
2016
125
0.270
Why?
Health Status Indicators
1
2007
155
0.270
Why?
Pentosan Sulfuric Polyester
1
2006
1
0.260
Why?
Economics, Pharmaceutical
1
2006
10
0.260
Why?
Cystitis, Interstitial
1
2006
16
0.260
Why?
Drug Resistance, Fungal
2
2017
9
0.260
Why?
Endometriosis
2
2017
40
0.250
Why?
Prostatic Neoplasms
2
2012
913
0.240
Why?
Urinary Incontinence
1
2005
56
0.240
Why?
Immunoglobulin G
1
2008
766
0.240
Why?
Recurrence
3
2020
925
0.230
Why?
Treatment Outcome
12
2017
9049
0.230
Why?
Psychotic Disorders
1
2005
114
0.220
Why?
Antibodies, Monoclonal, Humanized
7
2012
660
0.220
Why?
Drug Therapy, Combination
4
2015
949
0.210
Why?
Population Surveillance
1
2005
385
0.200
Why?
Adolescent
17
2017
17800
0.190
Why?
Anti-Inflammatory Agents
3
2011
445
0.190
Why?
Biological Products
2
2016
166
0.190
Why?
Bone Density Conservation Agents
2
2012
62
0.190
Why?
Gastritis
1
2022
84
0.190
Why?
Giant Cell Tumor of Tendon Sheath
1
2021
2
0.190
Why?
Enteritis
1
2022
82
0.190
Why?
Adenocarcinoma
1
2007
787
0.180
Why?
Gout Suppressants
2
2012
20
0.180
Why?
Tumor Necrosis Factor-alpha
4
2009
1128
0.180
Why?
Hemophilia B
1
2021
36
0.180
Why?
Hemophilia A
1
2021
67
0.180
Why?
Eosinophilia
1
2022
186
0.170
Why?
Genetic Therapy
1
2021
256
0.170
Why?
National Health Programs
1
2019
20
0.170
Why?
Voriconazole
2
2016
24
0.170
Why?
Technology Assessment, Biomedical
1
2019
29
0.170
Why?
Idiopathic Pulmonary Fibrosis
2
2015
500
0.170
Why?
Regression Analysis
4
2012
945
0.170
Why?
Aging
1
2009
1611
0.160
Why?
Myelodysplastic Syndromes
1
2021
119
0.160
Why?
Microbial Sensitivity Tests
2
2017
300
0.160
Why?
Nitriles
2
2016
149
0.150
Why?
Treatment Failure
2
2017
330
0.150
Why?
Overweight
1
2022
473
0.150
Why?
Vital Capacity
2
2015
254
0.150
Why?
Emergency Service, Hospital
3
2014
1815
0.150
Why?
Polystyrenes
1
2018
36
0.150
Why?
Mental Disorders
1
2005
889
0.140
Why?
Potassium
1
2018
127
0.140
Why?
4-Aminopyridine
1
2017
21
0.140
Why?
Antihypertensive Agents
2
2011
428
0.140
Why?
Retreatment
1
2017
67
0.140
Why?
Administration, Intravenous
1
2017
122
0.140
Why?
Patient Compliance
2
2011
524
0.140
Why?
Aspergillosis
1
2016
23
0.140
Why?
Consumer Behavior
1
2017
65
0.140
Why?
Abiraterone Acetate
1
2016
14
0.140
Why?
Hysterectomy
1
2017
105
0.130
Why?
Chronic Disease
3
2014
1577
0.130
Why?
Administrative Claims, Healthcare
1
2016
22
0.130
Why?
Health Care Rationing
1
2016
45
0.130
Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
40
0.130
Why?
Aromatase Inhibitors
1
2016
49
0.130
Why?
Time-to-Treatment
1
2017
146
0.130
Why?
Ambulatory Care
3
2015
479
0.130
Why?
Capecitabine
1
2016
45
0.130
Why?
Clinical Protocols
1
2017
232
0.130
Why?
Patient Admission
1
2017
175
0.130
Why?
Prednisone
1
2016
229
0.130
Why?
Disability Evaluation
1
2017
271
0.130
Why?
Waiting Lists
1
2017
206
0.120
Why?
Logistic Models
2
2014
1829
0.120
Why?
International Classification of Diseases
1
2016
116
0.120
Why?
Cross-Sectional Studies
3
2019
4402
0.120
Why?
Ki-1 Antigen
1
2015
4
0.120
Why?
Androstadienes
1
2015
97
0.120
Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
16
0.120
Why?
Drug Interactions
1
2016
337
0.120
Why?
California
2
2006
351
0.120
Why?
Follow-Up Studies
5
2015
4392
0.120
Why?
Leukemia, Myeloid, Acute
1
2021
533
0.120
Why?
Ribavirin
1
2015
89
0.120
Why?
Drug Administration Schedule
3
2011
714
0.110
Why?
Recombinant Proteins
1
2017
1228
0.110
Why?
International Normalized Ratio
1
2014
42
0.110
Why?
Heparin, Low-Molecular-Weight
1
2014
26
0.110
Why?
Amphotericin B
1
2014
28
0.110
Why?
Insurance, Health, Reimbursement
1
2014
88
0.110
Why?
Pulmonary Disease, Chronic Obstructive
2
2011
907
0.110
Why?
Immunoconjugates
1
2015
87
0.110
Why?
Constipation
1
2014
75
0.110
Why?
Drug Prescriptions
1
2015
237
0.110
Why?
Recovery of Function
1
2017
573
0.110
Why?
China
1
2014
161
0.110
Why?
ErbB Receptors
2
2016
554
0.110
Why?
Mycoses
1
2014
66
0.110
Why?
Models, Theoretical
1
2017
513
0.110
Why?
Morpholines
1
2014
102
0.110
Why?
Pyridines
1
2016
419
0.110
Why?
Thiophenes
1
2014
108
0.110
Why?
Drug Combinations
2
2011
286
0.110
Why?
Hodgkin Disease
1
2015
121
0.110
Why?
Warfarin
1
2014
136
0.110
Why?
Laparoscopy
1
2017
395
0.100
Why?
Budgets
1
2012
14
0.100
Why?
Multivariate Analysis
4
2015
1422
0.100
Why?
Allopurinol
1
2012
53
0.100
Why?
Health Status
2
2008
716
0.100
Why?
Gastrointestinal Diseases
1
2014
182
0.100
Why?
Adalimumab
5
2011
44
0.100
Why?
Lisdexamfetamine Dimesylate
1
2012
4
0.100
Why?
Multiple Sclerosis
1
2017
372
0.100
Why?
Estradiol
1
2015
450
0.100
Why?
Neoplasm Staging
1
2015
1162
0.100
Why?
Rivaroxaban
1
2014
211
0.100
Why?
Immunocompromised Host
1
2014
192
0.100
Why?
Databases as Topic
2
2009
63
0.100
Why?
Patient Readmission
1
2017
607
0.100
Why?
Medicaid
2
2006
404
0.100
Why?
Sulfonylurea Compounds
1
2012
44
0.100
Why?
Communication
1
2017
734
0.100
Why?
Sirolimus
1
2012
181
0.090
Why?
Models, Statistical
2
2012
595
0.090
Why?
Fractures, Spontaneous
1
2011
13
0.090
Why?
Spinal Cord Compression
1
2011
17
0.090
Why?
Hypercalcemia
1
2011
19
0.090
Why?
Cost Sharing
1
2011
14
0.090
Why?
Efficiency
2
2011
84
0.090
Why?
Japan
2
2021
85
0.090
Why?
Bone Diseases, Metabolic
1
2011
53
0.090
Why?
Bone Neoplasms
1
2012
191
0.090
Why?
Antidepressive Agents, Second-Generation
1
2010
38
0.090
Why?
Severity of Illness Index
4
2012
2537
0.090
Why?
Surveys and Questionnaires
3
2021
4595
0.090
Why?
Obesity
1
2022
2505
0.090
Why?
Bronchodilator Agents
1
2011
239
0.080
Why?
Angiogenesis Inhibitors
1
2011
213
0.080
Why?
Administration, Oral
1
2012
725
0.080
Why?
Linear Models
1
2012
768
0.080
Why?
Antidepressive Agents
1
2011
195
0.080
Why?
Case-Control Studies
2
2014
3003
0.080
Why?
Gastrointestinal Agents
1
2009
60
0.080
Why?
Time Factors
2
2017
6077
0.080
Why?
Etanercept
1
2008
51
0.080
Why?
Blood Chemical Analysis
1
2009
90
0.080
Why?
Age Distribution
3
2015
341
0.080
Why?
Receptors, Tumor Necrosis Factor
1
2008
140
0.080
Why?
Employment
2
2007
137
0.070
Why?
Clinical Trials as Topic
1
2012
926
0.070
Why?
Digestive System Surgical Procedures
1
2008
91
0.070
Why?
Quality-Adjusted Life Years
2
2022
103
0.070
Why?
Child
4
2020
18401
0.070
Why?
Veterans Disability Claims
1
2006
1
0.070
Why?
Health Benefit Plans, Employee
1
2006
20
0.070
Why?
Private Sector
1
2006
51
0.070
Why?
Coronary Disease
1
2008
348
0.060
Why?
Cohort Studies
2
2012
4883
0.060
Why?
Employer Health Costs
1
2005
4
0.060
Why?
Metabolic Diseases
1
2007
98
0.060
Why?
Ischemic Attack, Transient
1
2006
62
0.060
Why?
Hallucinations
1
2005
30
0.060
Why?
Colorectal Neoplasms
1
2011
592
0.060
Why?
Area Under Curve
1
2005
273
0.060
Why?
Carcinoma, Non-Small-Cell Lung
1
2012
959
0.060
Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
230
0.060
Why?
Metabolic Syndrome
1
2007
320
0.060
Why?
Asthma
2
2007
2021
0.060
Why?
Age Factors
2
2015
2885
0.060
Why?
Adrenal Cortex Hormones
1
2007
493
0.060
Why?
Data Collection
1
2006
618
0.050
Why?
Lung
1
2015
3521
0.050
Why?
Psychiatric Status Rating Scales
1
2005
481
0.050
Why?
Drug Resistance, Neoplasm
1
2007
636
0.050
Why?
Interviews as Topic
1
2005
575
0.050
Why?
Anti-Asthmatic Agents
1
2006
348
0.050
Why?
Health Policy
1
2005
330
0.050
Why?
Glucagon-Like Peptides
1
2022
22
0.050
Why?
Mental Health Services
1
2005
316
0.050
Why?
Double-Blind Method
3
2011
1656
0.050
Why?
Incidence
1
2006
2314
0.040
Why?
Asia
1
2019
53
0.040
Why?
Disease Progression
2
2015
2371
0.040
Why?
Administration, Inhalation
2
2011
637
0.040
Why?
Potassium Channel Blockers
1
2017
29
0.040
Why?
Disease Management
2
2015
556
0.040
Why?
Models, Econometric
1
2016
34
0.030
Why?
Delayed-Action Preparations
1
2017
158
0.030
Why?
Itraconazole
1
2016
7
0.030
Why?
B-Lymphocytes
1
2020
762
0.030
Why?
Cardiovascular Diseases
1
2007
1726
0.030
Why?
Utilization Review
1
2014
34
0.030
Why?
Early Diagnosis
1
2015
217
0.030
Why?
Dose-Response Relationship, Drug
2
2009
1836
0.030
Why?
Forced Expiratory Volume
1
2015
471
0.030
Why?
Hypothyroidism
1
2014
65
0.030
Why?
Aspergillus
1
2014
16
0.030
Why?
Cryptococcus
1
2014
7
0.030
Why?
Anemia, Iron-Deficiency
1
2014
53
0.030
Why?
Peripheral Vascular Diseases
1
2014
97
0.030
Why?
Mood Disorders
1
2014
112
0.030
Why?
Acute Disease
1
2015
907
0.030
Why?
Biopsy
1
2015
1024
0.020
Why?
Molecular Targeted Therapy
1
2015
347
0.020
Why?
Risk
1
2014
810
0.020
Why?
Matched-Pair Analysis
1
2011
33
0.020
Why?
Critical Care
1
2015
472
0.020
Why?
Nervous System Diseases
1
2014
254
0.020
Why?
Length of Stay
1
2015
957
0.020
Why?
Cetuximab
1
2011
90
0.020
Why?
Bevacizumab
1
2011
114
0.020
Why?
Tablets
1
2010
36
0.020
Why?
State Medicine
1
2009
18
0.020
Why?
Sex Factors
1
2015
1706
0.020
Why?
Epidemiologic Methods
1
2009
72
0.020
Why?
Remission Induction
1
2009
233
0.020
Why?
United Kingdom
1
2009
226
0.020
Why?
Insurance Coverage
1
2010
199
0.020
Why?
Injections, Subcutaneous
1
2009
134
0.020
Why?
Maximum Tolerated Dose
1
2009
183
0.020
Why?
Odds Ratio
1
2011
951
0.020
Why?
Europe
1
2009
332
0.020
Why?
Probability
1
2009
286
0.020
Why?
Statistics, Nonparametric
1
2009
384
0.020
Why?
Longitudinal Studies
1
2014
2384
0.020
Why?
Canada
1
2009
320
0.020
Why?
Prognosis
1
2015
3315
0.020
Why?
Confidence Intervals
1
2008
302
0.020
Why?
Reference Values
1
2009
739
0.020
Why?
Sex Distribution
1
2008
336
0.020
Why?
Randomized Controlled Trials as Topic
1
2012
1204
0.020
Why?
Models, Biological
1
2014
1611
0.020
Why?
Tomography, X-Ray Computed
1
2015
2272
0.020
Why?
Health Status Disparities
1
2008
200
0.020
Why?
Infant
2
2007
7943
0.010
Why?
Child, Preschool
2
2007
9114
0.010
Why?
Emergency Medical Services
1
2007
581
0.010
Why?
Risk Assessment
1
2009
2958
0.010
Why?
Body Mass Index
1
2007
1957
0.010
Why?
Infant, Newborn
1
2006
5038
0.010
Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)